Faslodex Post Marketing Surveillance.

Trial Profile

Faslodex Post Marketing Surveillance.

Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Dec 2010 Planned end date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 16 Mar 2009 Actual initiation date changed from Mar 2009 to Feb 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top